The Université de Sherbrooke is offering a PhD position in Medicinal Chemistry, focusing on GPCRs and chronic pain. The research groups, led by Professor Pierre-Luc Boudreault (Université de Sherbrooke) and co-supervised by Professor Michel Bouvier (Université de Montréal), are working on a new therapeutic target to develop safer alternatives to opioids. The project centers on the ACKR3 receptor, a G protein-coupled receptor that modulates the body's pain-relieving mechanisms. By targeting ACKR3, the team aims to restore and enhance natural pain control, providing a promising strategy for chronic pain treatment.

The PhD candidate will engage in structure–activity relationship (SAR) studies, solution-phase organic synthesis, solid-phase peptide and macrocyclic synthesis, and molecular modeling. The design and synthesis of new molecules will be supported by molecular modeling, with compounds evaluated in vitro and in vivo for biological activity and pain model efficacy. The candidate will be responsible for the chemistry aspects of the project and will receive interdisciplinary training in medicinal chemistry, molecular modeling, and GPCR pharmacology.

Applicants should hold an MSc in organic chemistry, pharmacy, biochemistry, or a related field, and demonstrate knowledge or strong interest in organic synthesis and peptide chemistry. Skills in molecular modeling and a good command of scientific English, writing, and communication are required. The project involves close collaboration with biologists, so the ability to work in a multidisciplinary environment is essential.

To apply, candidates should send a CV and cover letter to [email protected]. More information is available at Boudreault Lab. Applications are considered on a rolling basis, with a start date of May–June 2026 or earlier. Only selected candidates will be contacted.

Keywords: Medicinal Chemistry, GPCR, Chronic Pain, Organic Synthesis, Peptide Chemistry, Molecular Modeling, Pharmacology, ACKR3 Receptor.